Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
UNIVERSITE CLAUDE BERNARD - LYON 1 maintains a concentrated patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action, which is assigned to a single examiner. This singular focus suggests that the organization's immediate legal efforts are directed toward a specific set of claims or a single invention rather than a broad array of simultaneous filings.
The data shows that 1 distinct examiner and 1 distinct art unit are involved in the current workload. WARD, AARON DUREL serves as the busiest examiner for the portfolio, responsible for 1 pending office action. This 1 to 1 ratio between the total pending actions and those assigned to the busiest examiner indicates that the entirety of the portfolio's active prosecution is under the purview of one individual. Such concentration can lead to a more consistent dialogue between the applicant and the USPTO.
Practitioners should note that the involvement of 1 distinct art unit means the technical evaluation is localized within a specific USPTO division. Because there is only 1 pending office action, the portfolio does not currently face a broad range of simultaneous examiner interactions. The presence of WARD, AARON DUREL as the sole examiner for the active matters simplifies the communication strategy for the applicant. This structure allows for a highly targeted approach to resolving the outstanding issues in the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAM, JIEUN | 1 | 50.0% | +8.8% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035239 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE PROLIFERATIVE CAPACITY OF T LYMPHOCYTES | SWITZER, JULIET CAROLINE | 31d overdue |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | FRITCHMAN, REBECCA M | 5d |
| 18285175 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | HAM, JIEUN | — |
| 18038385 | RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS | SITTON, JEHANNE SOUAYA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035239 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE PROLIFERATIVE CAPACITY OF T LYMPHOCYTES | SWITZER, JULIET CAROLINE | 31d overdue |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | FRITCHMAN, REBECCA M | 5d |
| 17040246 | METHOD FOR REPROGRAMMING SOMATIC CELLS | BERTOGLIO, VALARIE E | 12d |
| 18038385 | RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS | SITTON, JEHANNE SOUAYA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1699 | 1 |
| 1682 | 1 |
| 1758 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285175 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | HAM, JIEUN | 1643 | §102§103§112Other | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18038385 | RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS | SITTON, JEHANNE SOUAYA | 1699 | §101§112 | Non-Final OA | — | Pending | May 23, 2023 |
| 18035239 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE PROLIFERATIVE CAPACITY OF T LYMPHOCYTES | SWITZER, JULIET CAROLINE | 1682 | §101§103 | Final Rejection | 31d overdue | Pending | May 03, 2023 |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 5d | Pending | Apr 01, 2022 |
| 17040246 | METHOD FOR REPROGRAMMING SOMATIC CELLS | BERTOGLIO, VALARIE E | 1632 | §112 | Final Rejection | 12d | Pending | Sep 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial